Two-stage randomized clinical trials with a right-censored endpoint: Comparison of frequentist and Bayesian adaptive designs.
Bayesian boundaries
adaptive design
combination test
interim analysis
survival trial
Journal
Statistics in medicine
ISSN: 1097-0258
Titre abrégé: Stat Med
Pays: England
ID NLM: 8215016
Informations de publication
Date de publication:
06 Jun 2024
06 Jun 2024
Historique:
revised:
17
04
2024
received:
21
09
2022
accepted:
20
05
2024
medline:
7
6
2024
pubmed:
7
6
2024
entrez:
6
6
2024
Statut:
aheadofprint
Résumé
Adaptive randomized clinical trials are of major interest when dealing with a time-to-event outcome in a prolonged observation window. No consensus exists either to define stopping boundaries or to combine
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Statistics in Medicine published by John Wiley & Sons Ltd.
Références
Armitage P. Sequential Medical Trials. Oxford, UK: Blackwell Scientific Publications; 1960.
Pocock SJ. Group sequential methods in the design and analysis of clinical trials. Biometrika. 1977;64(2):191‐199.
O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35(3):549‐556.
Lan KG, Demets DL. Group sequential procedures: calendar versus information time. Stat Med. 1989;8(10):1191‐1198.
Gordon Lan KK, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika. 1983;70(3):659‐663.
Pampallona S, Tsiatis AA, Kim K. Spending functions for the type I and type II error probabilities of group sequential tests. J Stat Plan Inference. 1995;49(19):1935‐1994.
Jennison C, Turnbull BW. Group Sequential Methods with Applications to Clinical Trials. Boca Raton, FL: CRC Press: Chapman & Hall; 1999.
Bauer P, Kohne K. Evaluation of experiments with adaptive interim analyses. Biometrics. 1994;50(4):1029‐1041.
Proschan MA, Hunsberger SA. Designed extension of studies based on conditional power. Biometrics. 1995;51(4):1315‐1324.
Bauer P, Bretz F, Dragalin V, König F, Wassmer G. Twenty‐five years of confirmatory adaptive designs: opportunities and pitfalls. Stat Med. 2016;35(3):325‐347.
Bhatt DL, Mehta C. Adaptive designs for clinical trials. N Engl J Med. 2016;375(1):65‐74.
Jörgens S, Wassmer G, König F, Posch M. Nested combination tests with a time‐to‐event endpoint using a short‐term endpoint for design adaptations. Pharm Stat. 2019;18(3):329‐350.
Posch M, Bauer P, Brannath W. Issues in designing flexible trials. Stat Med. 2003;22(6):953‐969.
Tsiatis AA, Mehta C. On the inefficiency of the adaptive design for monitoring clinical trials. Biometrika. 2003;90(2):367‐378.
Bauer P, Koenig F. The reassessment of trial perspectives from interim data—a critical view. Stat Med. 2006;25(1):23‐36.
Mehta CR, Pocock SJ. Adaptive increase in sample size when interim results are promising: a practical guide with examples. Stat Med. 2011;30(28):3267‐3284.
Müller H, Schäfer H. A general statistical principle for changing a design any time during the course of a trial. Stat Med. 2004;23(16):2497‐2508.
Brannath W, König F, Bauer P. Estimation in flexible two stage designs. Stat Med. 2006;25(19):3366‐3381.
Cui L, Hung HJ, Wang SJ. Modification of sample size in group sequential clinical trials. Biometrics. 1999;55(3):853‐857.
Lehmacher W, Wassmer G. Adaptive sample size calculations in group sequential trials. Biometrics. 1999;55(4):1286‐1290.
Posch M, Bauer P. Adaptive two stage designs and the conditional error function. Biometric J J Math Method Biosci. 1999;41(6):689‐696.
Müller HH, Schäfer H. Adaptive group sequential designs for clinical trials: combining the advantages of adaptive and of classical group sequential approaches. Biometrics. 2001;57(3):886‐891.
Bretz F, Schmidli H, König F, Racine A, Maurer W. Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: general concepts. Biom J. 2006;48(4):623‐634.
Magirr D, Jaki T, Koenig F, Posch M. Sample size reassessment and hypothesis testing in adaptive survival trials. PLoS One. 2016;11(2):1932‐6203.
Bauer P, Posch M. Modification of the sample size and the schedule of interim analyses in survival trials based on data inspections by H. Schäfer and H.‐H. Mäller,Statistics in medicine 2001;20: 3741–3751. Stat Med. 2004;23(8):1333‐1334.
Jahn‐Eimermacher A, Ingel K. Adaptive trial design: a general methodology for censored time to event data. Contemp Clin Trials. 2009;30(2):171‐177.
Desseaux K, Porcher R. Flexible two‐stage design with sample size reassessment for survival trials. Stat Med. 2007;26(27):5002‐5013.
Wassmer G. Planning and analyzing adaptive group sequential survival trials. Biom J. 2006;48(4):714‐729.
Emerson SS, Kittelson JM, Gillen DL. Frequentist evaluation of group sequential clinical trial designs. Stat Med. 2007;26(28):5047‐5080.
Stallard N, Todd S, Ryan EG, Gates S. Comparison of Bayesian and frequentist group‐sequential clinical trial designs. BMC Med Res Methodol. 2020;20:1‐14.
Freedman LS, Spiegelhalter DJ. Comparison of Bayesian with group sequential methods for monitoring clinical trials. Control Clin Trials. 1989;10(4):357‐367.
Brard C, Le Teuff G, Le Deley MC, Hampson LV. Bayesian survival analysis in clinical trials: what methods are used in practice? Clin Trials. 2017;14(1):78‐87.
Inoue LY, Thall PF, Berry DA. Seamlessly expanding a randomized phase II trial to phase III. Biometrics. 2002;58(4):823‐831.
Di Scala L, Glimm E. Time‐to‐event analysis with treatment arm selection at interim. Stat Med. 2011;30(26):3067‐3081.
Schmidli H, Bretz F, Racine A, Maurer W. Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: applications and practical considerations. Biom J. 2006;48(4):635‐643.
FDA. Adaptive Designs for Clinical Trials of Drugs and Biologics: Guidance for Industry. White Oak, MD: FDA; 2019.
Ryan EG, Brock K, Gates S, Slade D. Do we need to adjust for interim analyses in a Bayesian adaptive trial design? BMC Med Res Methodol. 2020;20:1‐9.
EMA. Guidelines on Clinical Trials in Small Populations. Amsterdam, Netherlands: EMA; 2006.
Hilgers RD, Roes K, Stallard N. Directions for new developments on statistical design and analysis of small population group trials. Orphanet J Rare Dis. 2016;11:1‐10.
Kidwell KM, Roychoudhury S, Wendelberger B, et al. Application of Bayesian methods to accelerate rare disease drug development: scopes and hurdles. Orphanet J Rare Dis. 2022;17(1):186.
Campbell G, Irony T, Pennello G, Thompson L. Bayesian statistics for medical devices: progress since 2010. Ther Innov Regul Sci. 2023;57(3):453‐463.
Travis J, Rothmann M, Thomson A. Perspectives on informative Bayesian methods in pediatrics. J Biopharm Stat. 2023;33(6):830‐843.
Shord SS, Zhu H, Liu J, Rahman A, Booth B, Zineh I. US Food and Drug Administration embraces using innovation to identify optimized dosages for patients with cancer. CPT Pharmacometrics Syst Pharmacol. 2023;12(11):1573.
Jack Lee J, Chu CT. Bayesian clinical trials in action. Stat Med. 2012;31(25):2955‐2972.
Brophy JM, Joseph L. Placing trials in context using Bayesian analysis: GUSTO revisited by reverend Bayes. J Am Stat Assoc. 1995;273(11):871‐875.
Berry DA. Bayesian clinical trials. Nat Rev Drug Discov. 2006;5(1):27‐36.
Fisher LD. Comments on Bayesian and frequentist analysis and interpretation of clinical trials. Control Clin Trials. 1996;17(5):423‐434.
Gelman A, Carlin JB, Stern HS, Rubin DB. Bayesian Data Analysis. Boca Raton, FL: Chapman and Hall/CRC; 1995.
Freedman LS, Spiegelhalter DJ, Parmar MK. The what, why and how of Bayesian clinical trials monitoring. Stat Med. 1994;13(13–14):1371‐1383.
Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid‐19 vaccine. N Engl J Med. 2020;383(27):2603‐2615.
Chevret S. Bayesian adaptive clinical trials: a dream for statisticians only? Stat Med. 2012;31:1002‐1013.
Dartigeas C, Van Den Neste E, Léger J, et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open‐label, randomised phase 3 study. Lancet Haematol. 2018;5(2):e82‐e94.
Lan KG, Lachin JM. Implementation of group sequential logrank tests in a maximum duration trial. Biometrics. 1990;46(3):759‐770.
Demets DL, Lan KG. Interim analysis: the alpha spending function approach. Stat Med. 1994;13(13‐14):1341‐1352.
Tsiatis AA. The asymptotic joint distribution of the efficient scores test for the proportional hazards model calculated over time. Biometrika. 1981;68(1):311‐315.
Spiegelhalter DJ, Freedman LS, Parmar MK. Bayesian approaches to randomized trials. J R Stat Soc Ser A. 1994;157(3):357‐387.
Fayers PM, Ashby D, Parmar MK. Tutorial in biostatistics: Bayesian data monitoring in clinical trials. Stat Med. 1997;16(12):1413‐1430.
Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian Approaches to Clinical Trials and Health‐Care Evaluation. Vol 13. Hoboken, NJ: John Wiley & Sons; 2004.
Grossman J, Parmar MK, Spiegelhalter DJ, Freedman LS. A unified method for monitoring and analysing controlled trials. Stat Med. 1994;13(18):1815‐1826.
Schoenfeld D. The asymptotic properties of nonparametric tests for comparing survival distributions. Biometrika. 1981;68(1):316‐319.
Schoenfeld DA. Sample‐size formula for the proportional‐hazards regression model. Biometrics. 1983;37(2):499‐503.
Jones D, Whitehead J. Sequential forms of the log rank and modified Wilcoxon tests for censored data. Biometrika. 1979;66(1):105‐113.
Wassmer G. Multistage adaptive test procedures based on Fisher's product criterion. Biometric J J Math Method Biosci. 1999;41(3):279‐293.
Yin G, Lam CK, Shi H. Bayesian randomized clinical trials: from fixed to adaptive design. Contemp Clin Trials. 2017;59:77‐86.
Armitage P, Berry G, Matthews JNS. Statistical Methods in Medical Research. Hoboken, NJ: John Wiley and Sons; 2008.
Berry S, Carlin B, Lee J, Muller P. Bayesian Adaptive Methods for Clinical Trials. Boca Raton, FL: CRC Press; 2011.
Ryan E, Stallard N, Lall R, et al. Bayesian group sequential designs for phase III emergency medicine trials: a case study using the PARAMEDIC2 trial. Trials. 2020;21(1):1‐13.